These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 27084761)

  • 1. The association of lung function and St. George's respiratory questionnaire with exacerbations in COPD: a systematic literature review and regression analysis.
    Martin AL; Marvel J; Fahrbach K; Cadarette SM; Wilcox TK; Donohue JF
    Respir Res; 2016 Apr; 17():40. PubMed ID: 27084761
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early response to inhaled bronchodilators and corticosteroids as a predictor of 12-month treatment responder status and COPD exacerbations.
    Calverley PM; Postma DS; Anzueto AR; Make BJ; Eriksson G; Peterson S; Jenkins CR
    Int J Chron Obstruct Pulmon Dis; 2016; 11():381-90. PubMed ID: 26952309
    [TBL] [Abstract][Full Text] [Related]  

  • 3. COPD exacerbations and patient-reported outcomes according to post-bronchodilator FEV
    Chai CS; Ng DL; Bt Mos S; Ibrahim MAB; Tan SB; Pang YK; Liam CK
    BMC Pulm Med; 2023 Apr; 23(1):150. PubMed ID: 37118725
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationships between symptoms and lung function in asthma and/or chronic obstructive pulmonary disease in a real-life setting: the NOVEL observational longiTudinal studY.
    Papi A; Hughes R; Del Olmo R; Agusti A; Chipps BE; Make B; Tomaszewski E; Peres Da Costa K; Srivastava D; Vestbo J; Janson C; Burgel PR; Price D
    Ther Adv Respir Dis; 2024; 18():17534666241254212. PubMed ID: 38841799
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rescue medication use as a patient-reported outcome in COPD: a systematic review and regression analysis.
    Punekar YS; Sharma S; Pahwa A; Takyar J; Naya I; Jones PW
    Respir Res; 2017 May; 18(1):86. PubMed ID: 28482883
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhaled corticosteroids with combination inhaled long-acting beta2-agonists and long-acting muscarinic antagonists for chronic obstructive pulmonary disease.
    van Geffen WH; Tan DJ; Walters JA; Walters EH
    Cochrane Database Syst Rev; 2023 Dec; 12(12):CD011600. PubMed ID: 38054551
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fluticasone propionate/formoterol for COPD management: a randomized controlled trial.
    Papi A; Dokic D; Tzimas W; Mészáros I; Olech-Cudzik A; Koroknai Z; McAulay K; Mersmann S; Dalvi PS; Overend T
    Int J Chron Obstruct Pulmon Dis; 2017; 12():1961-1971. PubMed ID: 28740376
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Can roflumilast, a phosphodiesterase-4 inhibitor, improve clinical outcomes in patients with moderate-to-severe chronic obstructive pulmonary disease? A meta-analysis.
    Luo J; Wang K; Liu D; Liang BM; Liu CT
    Respir Res; 2016 Feb; 17():18. PubMed ID: 26887407
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prophylactic antibiotics for adults with chronic obstructive pulmonary disease: a network meta-analysis.
    Janjua S; Mathioudakis AG; Fortescue R; Walker RA; Sharif S; Threapleton CJ; Dias S
    Cochrane Database Syst Rev; 2021 Jan; 1(1):CD013198. PubMed ID: 33448349
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Indacaterol/glycopyrronium versus salmeterol/fluticasone in Asian patients with COPD at a high risk of exacerbations: results from the FLAME study.
    Wedzicha JA; Zhong N; Ichinose M; Humphries M; Fogel R; Thach C; Patalano F; Banerji D
    Int J Chron Obstruct Pulmon Dis; 2017; 12():339-349. PubMed ID: 28176893
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduction in clinically important deterioration in chronic obstructive pulmonary disease with aclidinium/formoterol.
    Singh D; D'Urzo AD; Chuecos F; Muñoz A; Garcia Gil E
    Respir Res; 2017 May; 18(1):106. PubMed ID: 28558833
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term health-related quality-of-life and symptom response profiles with arformoterol in COPD: results from a 52-week trial.
    Donohue JF; Bollu VK; Stull DE; Nelson LM; Williams VS; Stensland MD; Hanania NA
    Int J Chron Obstruct Pulmon Dis; 2018; 13():499-508. PubMed ID: 29440887
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlations between FEV1 and patient-reported outcomes: A pooled analysis of 23 clinical trials in patients with chronic obstructive pulmonary disease.
    Donohue JF; Jones PW; Bartels C; Marvel J; D'Andrea P; Banerji D; Morris DG; Patalano F; Fogel R
    Pulm Pharmacol Ther; 2018 Apr; 49():11-19. PubMed ID: 29277690
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tiotropium versus ipratropium bromide for chronic obstructive pulmonary disease.
    Cheyne L; Irvin-Sellers MJ; White J
    Cochrane Database Syst Rev; 2013 Sep; (9):CD009552. PubMed ID: 24043433
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-acting beta2-agonist in addition to tiotropium versus either tiotropium or long-acting beta2-agonist alone for chronic obstructive pulmonary disease.
    Farne HA; Cates CJ
    Cochrane Database Syst Rev; 2015 Oct; (10):CD008989. PubMed ID: 26490945
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Benefits and risks of adjunctive inhaled corticosteroids in chronic obstructive pulmonary disease: a meta-analysis.
    Sobieraj DM; White CM; Coleman CI
    Clin Ther; 2008 Aug; 30(8):1416-25. PubMed ID: 18803985
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Umeclidinium bromide versus placebo for people with chronic obstructive pulmonary disease (COPD).
    Ni H; Htet A; Moe S
    Cochrane Database Syst Rev; 2017 Jun; 6(6):CD011897. PubMed ID: 28631387
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Deterioration of quality of life is associated with the exacerbation frequency in individuals with alpha-1-antitrypsin deficiency - analysis from the German Registry.
    Bernhard N; Lepper PM; Vogelmeier C; Seibert M; Wagenpfeil S; Bals R; Fähndrich S
    Int J Chron Obstruct Pulmon Dis; 2017; 12():1427-1437. PubMed ID: 28553095
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of frequency of COPD exacerbations on pulmonary function, health status and clinical outcomes.
    Anzueto A; Leimer I; Kesten S
    Int J Chron Obstruct Pulmon Dis; 2009; 4():245-51. PubMed ID: 19657398
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunostimulants versus placebo for preventing exacerbations in adults with chronic bronchitis or chronic obstructive pulmonary disease.
    Fraser A; Poole P
    Cochrane Database Syst Rev; 2022 Nov; 11(11):CD013343. PubMed ID: 36373977
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.